An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)
CompletedPhase 4NCT01811186
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Objectives: 1. Objective of main interest \- To assess the drop-out rate caused by adverse event\* after 6 weeks treatment 2. Further objectives * To assess the drop-out rate caused by adverse event\* after 1 week treatment * To assess the pain reduction rate after 6 weeks treatment from baseline * To assess the Euroquol (EQ-5D) quality of life * To assess physician's overall satisfaction * To assess subject's overall satisfaction * To assess safety
Study details
- Official title
- An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With Targin® in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)
- Conditions
- Interventions
- Sponsor
- Mundipharma Korea Ltd
- Start date
- 2012-12
- Primary completion
- 2014-01
- Sex
- All
- Age range
- from 20 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- South Korea
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female ≥ 20 and \<80 years of age * Patients who have non-malignant chronic pain(≥90 days) * Patients who have moderate to severe pain intensity which is not controlled with non-strong opioid * Naïve patients for Oxycodone/Naloxone (Naïve patient defined as who did not treated for 90 days) * Naïve patients for strong opioid (Naïve patient defined as who did not treated for 90 days) * Patients who signed a written informed consent form Exclusion Criteria: * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test * Patients with known hypersensitivity to Oxycodone/Naloxone or to any of the excipients * Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment * Having used other investigational drugs at the time of enrollment, or within 30 days of enrollment
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01811186